Webinar: Using Social Media to Advance Your Career

Joel M. Gelfand MD MSCE is Professor of Dermatology and Epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 260 scientific publications, editorials, reviews, and text book chapters (cited over 18,000 times, H index 60) which appear in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is a past Associate Editor of Pharmacoepidemiology and Drug Safety, past Editorial Board Member of the Journal of the American Academy of Dermatology, and is currently Deputy Editor of the Journal Investigative Dermatology. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s New Investigator Marjorie Bowman Award and the Lady Barbara Colyton’s Award for Autoimmune research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, National Psoriasis Foundation’s (NPF)  inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation. He Co-Chairs the NPF’s COVID-19 task force, and is a member of the Board of Directors for the International Psoriasis Council. He is a co-author of the AAD-NPF joint guidelines of care for psoriasis. He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the NPF, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.

Dr. Harris is the Chair of Dermatology, Founding Director of the Vitiligo Clinic and Research Center, and Founding Director of the Autoimmune Therapeutics Institute at UMass Medical School in Worcester, Massachusetts. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a large research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, early clinical trials in vitiligo have shown success, and more are being developed. Finally, Dr. Harris founded Villaris Therapeutics, whose entire focus is to develop an effective, long-lasting treatment for vitiligo.

Dr. Daniel Sugai was born and raised on the Hawaiian island of Oahu where he studied biology and art in college at the University of Hawaii. He then went on and got his M.D. from the University of Hawaii and was Class President and President of his school’s AOA Honor Society. He completed his dermatology training in the Harvard Combined Dermatology Residency Program where he trained at Mass General Hospital/BWH/Beth Israel Deaconess Medical Center/Boston Children’s Hospital. Upon graduating from residency and passing his board certification examination, he moved to Seattle, WA and practices medical, cosmetic and surgical dermatology- seeing pediatrics and adults. He received multiple “Top Doctor” accolades including Seattle Met Magazine Top Doctor 2020. At the start of the pandemic in March/April 2020, Dr. Sugai started a YouTube channel, Instagram and TikTok to help disseminate credible science-backed skin education to the masses. It has become a “second job” and a passion of his and he enjoys connecting with people from all around the globe.